Raw totals tell one story about Obama's debt legacy, but ranking presidents by annual pace reshapes the list in ways most people never see. Three terms sit above him, and two belong to the…
Bitcoin and Ethereum are barely moving this Tuesday, yet the stocks built around them are crashing open sharply lower. A shock from an unexpected corner of the market explains why crypto equities are suddenly…
SpaceX is now publicly traded and sitting just outside the reach of the world's largest ETF, and the rulebook keeping it out raises real questions about what VOO holders should do while they wait.
YouTuber Markiplier's surprise stake in GoPro has sent shares on a two-day tear, but a going-concern warning, a looming dilution overhang, and a sell-side consensus price target well below the current price suggest the…
A global bond selloff sent long-term yields surging to levels not seen in over a year, and the chips sector is bearing the brunt as traders reprice the market's most ambitious AI growth bets.
Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.
Kevin Warsh just sent September rate hike odds above 50%, but at least one prominent investor thinks the bond market is making a serious mistake and that NVIDIA traders may be the ones who…
Seagate has already handed investors gains that dwarf Nvidia's returns over the past year, and Wall Street analysts think the storage giant still has a long way to run before this AI trade exhausts…
Broadcom sits 25% below its peak while 44 Wall Street analysts line up behind a price target that towers above the current price, and one respected firm sees something in the backlog numbers that…
KRE bundles roughly 140 regional banks into one tidy package, but that diversification comes at a quiet cost to dividend growth and total return that most income investors never stop to measure.
Apple's next CEO inherits a trillion-dollar empire and a glaring weakness that rivals have exploited for years. A top tech analyst says fixing one product could determine whether Apple leads the AI era or…
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
Goldman Sachs builds its Conviction List by identifying stocks where analysts hold their highest confidence in outperformance, and this month's screen turned up five dividend payers with yields that income investors rarely find attached…
Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make.
XLC carries the word "communication" in its name, but the fund's actual portfolio has almost nothing to do with phone bills, fiber lines, or fat dividend checks. Before you assume you own telecom income,…
